North America Autoinjectors Market Insights Forecasts to 2032

• The North America Autoinjectors Market Size was valued at USD multimillion in 2022.
• The Market is growing at a CAGR of 16.5% from 2022 to 2032

The North America Autoinjectors Market Size was valued at USD multimillion in 2022 at a CAGR of 16.5% during the forecast period (2022-2032).

Market Overview

Syringes with a pre-filled tip that is secured by spring makeup autoinjectors. It activates and delivers a precise amount of medication when a sliding motion is employed to inject the device into the body. In addition to conventional medical and emergency therapies, autoinjectors can be used to provide epinephrine to prevent anaphylaxis or immediately alleviate migraine discomfort. Autoinjectors provide several advantages, including reducing needle phobia, cutting down on needle sticks, maintaining constant dosage quality, and boosting self-confidence. Simplifying regulations has created opportunities for the autoinjectors business to expand in North America. The time and money required for product development and introduction have decreased thanks to regulatory organizations like the FDA who have simplified the approval procedure. This has sped up market entrance, reduced prices, increased innovation, and made it simpler for patients to access more cutting-edge autoinjector devices.  By attracting more participants, fostering innovation, and guaranteeing that patients receive better care more promptly, regulatory simplification has assisted the sector in expanding.

Report Coverage

This research report categorizes the market of the North America autoinjectors market based on various segments and regions and forecasts revenue growth and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the North America autoinjectors market. Recent market developments and competitive strategies such as expansion, product launch, and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segments of the North America autoinjectors market

Driving Factors

Medical intervention is required immediately for anaphylactic shock. Autoinjectors are devices that provide epinephrine in the event of an anaphylactic emergency. Food allergies, a major contributor to anaphylactic shock, are on the rise in the United States, according to the CDC. Moreover, the aging population in North America is expected to drive the demand for healthcare services and treatments. Autoinjectors are particularly beneficial for older adults who may have difficulties with manual injections, providing them with a more convenient and manageable option for medication administration. In addition, regulatory agencies in North America, such as the U.S. Food and Drug Administration (FDA) and Health Canada, have established guidelines and processes to streamline the approval and commercialization of autoinjectors. This favorable regulatory environment encourages innovation and market growth.

Restraining Factors

The pharmaceutical industry in North America has made advancements in transdermal patches, inhalation devices, and oral medications. These substitutes boost patient compliance, convenience, and demand for autoinjectors. In contrast to injections, patients may prefer oral or non-invasive administration methods. Oral medications are handy and well-known due to their extensive use. This inhibits market expansion.

Market Segment

• In 2022, the anaphylaxis segment is influencing the market with a higher growth rate during the forecast period

Based on the therapy, the North America autoinjectors market is bifurcated into anaphylaxis, psoriasis, and migraine. Among these, the anaphylaxis segment is expected to have a higher market share value over the forecast period The Anaphylaxis segment dominates the market and is expected to grow at a CAGR of 14.2% during the forecast period. Anaphylaxis refers to a severe and potentially life-threatening allergic reaction. Autoinjectors are commonly used in the treatment of anaphylaxis to deliver epinephrine (adrenaline) quickly and effectively. Epinephrine autoinjectors are designed to be easily self-administered in emergencies and are commonly used by individuals with known severe allergies, such as to insect stings, certain foods, or medications.

• In 2022, the disposable segment is dominating the largest market share over the forecast period.

Based on the type, the North America autoinjectors market is segmented into disposable and reusable. Among these, the disposable segment held the largest market share over the forecast period. Disposable dominated the market and is expected to register a CAGR of 14.5% over the forecast period. Disposable autoinjectors are designed for single use and are discarded after a single injection. They typically come pre-filled with specific medication and are often preferred for their convenience and ease of use. Disposable autoinjectors eliminate the need for manual loading of medication and are generally considered more hygienic. They are typically provided in ready-to-use formats and are popular among patients who require infrequent or occasional injections.

• In 2022, the hospitals and clinics segment is influencing the largest market share over the forecast period.

Based on the end users, the North America autoinjectors market is segmented into hospitals and clinics, home care, & others. Among these, the hospitals and clinics segment influences the largest market share during the forecast period. Autoinjectors may be utilized in various departments and specialties, including emergency departments, outpatient clinics, and specialty clinics. Hospitals and clinics often have the infrastructure and expertise to handle a variety of medical conditions, and autoinjectors can be used as part of treatment protocols for a range of diseases and disorders.

• In 2022, the United States segment is dominating the largest market growth over the projection period

Based on the country, the North America autoinjectors market is classified into the United States, Canada, Mexico, and the Rest of North America. Among these, the United States segment holds the largest market growth during the forecast period. The growth in chronic and particular illnesses, the number of regulatory approvals, and the development of technology in the healthcare sector are all contributing to the market's expansion. 33.1 million Americans are estimated to have food allergies, according to Food Allergy Research and Education. One in thirteen of them, or 5.99 million, are under the age of 18. The FDA must approve new drugs more swiftly due to the increased prevalence of anaphylaxis and other allergies in the country. Due to the rise in chronic and inflammatory disorders, self-administered medications are more in demand.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the North America autoinjectors market along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• Pfizer Inc. (Meridian Medical Technologies, Inc.)
• AbbVie Inc.
• Sanofi
• SHL Group
• Becton, Dickinson, and Company
• Biogen
• Mylan N.V.
• Novartis AG
• Antares Pharma

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Recent Development

• In May 2023, a new cell sorting device with two ground-breaking technologies was introduced by B.D. (Becton, Dickinson, and Company), a major player in the global medical technology market enabling scientists to learn more about cells than was previously feasible in flow cytometry tests.

• In April 2023, for the development of the commercial scale manufacturing process for the Company's proprietary lead product, AVERSATM Fentanyl, an abuse-deterrent fentanyl transdermal system, Nutriband Inc. and Kindeva Drug Delivery ("Kindeva") chose the target AVERSATM formulation.

Market Segment

This study forecasts revenue at global, regional, and country levels from 2022 to 2032. Spherical Insights has segmented the North America Autoinjectors Market based on the below-mentioned segments:

North America Autoinjectors Market, By Therapy

• Anaphylaxis
• Psoriasis
• Migraine

North America Autoinjectors Market, By Type

• Disposable

• Reusable

North America Autoinjectors Market, By End Users

• Hospitals 
• Clinics
• Home Care
• Others

North America Handbag Market, By Country

• United States
• Canada
• Mexico
•  Rest of North America